Scinai Immunotherapeutics Ltd. (SCNI)

Scinai Immunotherapeutics Income Statement

Financials in millions ILS. Fiscal year is January - December.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	5.3	7.63	4.71	2.74	1.45	1.38	1.16	0.96	0.75	0.62	Upgrade
Research & Development	5.77	3.25	14.53	19.38	20.3	5.3	2.2	2.23	1.55	1.54	Upgrade
Other Operating Expenses	0	-0.01	-21.31	0	0	0	0	0	0	-0	Upgrade
Operating Expenses	11.06	10.86	-2.07	22.11	21.75	6.68	3.36	3.19	2.3	2.16	Upgrade
Operating Income	-11.06	-10.86	2.07	-22.11	-21.75	-6.68	-3.36	-3.19	-2.3	-2.16	Upgrade
Interest Expense / Income	0	0	4.41	8.71	3.84	3.08	0.09	0.01	0	0.16	Upgrade
Other Expense / Income	-5.27	-2.66	-1.08	-0	-0.83	-0.01	-0.85	-0.32	-0.11	-0.04	Upgrade
Pretax Income	-5.8	-8.21	-1.26	-30.82	-24.76	-9.75	-2.59	-2.88	-2.19	-2.27	Upgrade
Net Income	-5.8	-8.21	-1.26	-30.82	-24.76	-9.75	-2.59	-2.88	-2.19	-2.27	Upgrade
Shares Outstanding (Basic)	754	565	443	327	261	201	135	106	54	48	Upgrade
Shares Outstanding (Diluted)	754	565	443	327	261	201	135	106	54	48	Upgrade
Shares Change	33.57%	27.37%	35.70%	24.95%	30.04%	48.80%	28.03%	94.38%	13.22%	15.45%	Upgrade
EPS (Basic)	-4.00	-8.00	-1.13	-37.26	-38.39	-19.19	-7.90	-11.29	-15.81	-19.19	Upgrade
EPS (Diluted)	-4.00	-8.00	-1.13	-37.26	-38.39	-19.19	-7.90	-11.29	-15.81	-19.19	Upgrade
Free Cash Flow	-8.1	-7.57	-22.16	-23.85	-22.8	-4.11	-2.73	-2.91	-2.15	-1.24	Upgrade
Free Cash Flow Per Share	-4.30	-5.36	-20.00	-29.20	-34.89	-8.18	-8.08	-11.02	-15.81	-10.36	Upgrade
EBITDA	-5.23	-7.74	3.84	-21.65	-20.85	-6.55	-2.33	-2.69	-2	-1.91	Upgrade
Depreciation & Amortization	0.56	0.47	0.69	0.46	0.07	0.12	0.18	0.18	0.19	0.2	Upgrade
EBIT	-5.8	-8.21	3.15	-22.11	-20.92	-6.67	-2.51	-2.87	-2.19	-2.11	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).